Oncolytic herpes simplex virus type 1 (HSV1) expressing GM-CSF [HSA:1437]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XL Antineoplastic cell and gene therapy
L01XL02 Talimogene laherparepvec
D09966 Talimogene laherparepvec (USAN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Antineoplastics, Other
Talimogene Laherparepvec
D09966 Talimogene laherparepvec (USAN)
New drug approvals in the USA [br08319.html]
Cellular and gene therapy products
D09966
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09966
Cellular and gene therapy products
D09966
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09966
